Skip to content
Screener

Corvus Pharmaceuticals CRVS Financing Cash Flow

Financing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$8.43B+777%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
-$1.22B-8.5%
AbbVie logo
AbbVieABBV
$919M+173%
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
$91K+1,111%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$1.1M+195%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$529.55M+7,564,886%

Other financials

Income statement

See full
Operating income-$14.9M-49.9%
Net income-$13.7M-190%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$40.1M+702%
Total debt$834.0K-27.7%
Total equity$240.7M+388%
Total assets$253.2M+326%

Cash flow

See full
Operating cash flow-$10.4M-25.5%
CapEx$91.0K+153%
Free cash flow-$10.5M-26.1%

Valuation

See full
Market cap$1.16B+243%
Enterprise value$1.12B+245%

Returns & leverage

See full
Return on equity-30.5%-12.5pp
Debt / equity0.0×
Current ratio19.8×+14.9×

Where this comes from

Reported directly by Corvus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Corvus Pharmaceuticals’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:05 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-057100
Line itemThree Months Ended / March 31, 2026Three Months Ended / March 31, 2025
Cash flows from financing activities
Proceeds from issuance of common stock in connection with follow-on public offering, net189,407
Proceeds from exercise of common stock options1,339279
Net cash provided by financing activities190,746279
Net increase (decrease) in cash and cash equivalents35,526(3,741)
Cash and cash equivalents at beginning of the period4,5768,740
Cash and cash equivalents at end of the period$40,102$4,999
Supplemental disclosures of cash flow information

Item 1. Financial Statements (unaudited)

FAQ

What is Corvus Pharmaceuticals's financing cash flow?
Corvus Pharmaceuticals (CRVS) reported financing cash flow of $190.75M in Q1 2026.
How has Corvus Pharmaceuticals's financing cash flow changed year-over-year?
Corvus Pharmaceuticals's financing cash flow increased by 68267.7% year-over-year, from $279K to $190.75M.
What is the long-term trend for Corvus Pharmaceuticals's financing cash flow?
Over 3 years (2021 to 2025), Corvus Pharmaceuticals's financing cash flow has grown at a -16.3% compound annual growth rate (CAGR), from $62.16M to $36.43M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Corvus Pharmaceuticals's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude